Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial / Raghu, Ganesh; Behr, Juergen; Brown, Kevin K; Egan, Jim J; Kawut, Steven M; Flaherty, Kevin R; Martinez, Fernando J; Nathan, Steven D; Wells, Athol U; Collard, Harold R; Costabel, Ulrich; Richeldi, Luca; de Andrade, Joao; Khalil, Nasreen; Morrison, Lake D; Lederer, David J; Shao, Lixin; Li, Xiaoming; Pedersen, Patty S; Montgomery, A. Bruce; Chien, Jason W; O'Riordan, Thomas G.. - In: ANNALS OF INTERNAL MEDICINE. - ISSN 0003-4819. - STAMPA. - 158:9(2013), pp. 641-649. [10.7326/0003-4819-158-9-201305070-00003]
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial
RICHELDI, Luca;
2013
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris